TMBR(Delisted)
TimberยทAMEX
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TMBR
Timber Pharmaceuticals, Inc.
A prescription and OTC products developer for the treatment of women's health and aesthetics dermatology
3 Mountain View Road, Suite 100, Warren, NJ 07059
--
Timber Pharmaceuticals, Inc., incorporated under the laws of Delaware, was originally established on August 30, 2010 in Nevada under the name of Thompson Design Company. The company has only one wholly-owned subsidiary, BioPharmX Corporation, a company incorporated in Nevada. Timber is a clinical-stage biopharmaceutical company focused on the development and commercialization of orphan skin disease treatments. The company's investigational therapies have proven mechanisms of action supported by decades of clinical experience and mature CMC (chemistry, manufacturing and control) and safety profiles. The company initially focused on developing non-systematic treatments for rare skin diseases, including congenital ichthyosis, or CI, including X-linked recessive CI, or XLRI, and autosomal recessive CI, or ARCI, and other sclerosing skin diseases.
Company Financials
EPS
TMBR has released its 2023 Q2 earnings. EPS was reported at -1.32, versus the expected 0, missing expectations. The chart below visualizes how TMBR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
